These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19483700)

  • 41. A truvada hypersensitivity reaction simulating abacavir hypersensitivity.
    de Perio MA; Gomez FJ; Frame PT; Fichtenbaum CJ
    AIDS; 2007 Oct; 21(16):2252-3. PubMed ID: 18090057
    [No Abstract]   [Full Text] [Related]  

  • 42. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preexposure prophylaxis for HIV infection.
    Steinbrook R
    JAMA; 2012 Sep; 308(9):865-6. PubMed ID: 22820712
    [No Abstract]   [Full Text] [Related]  

  • 44. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-HIV agents. No interaction between tenofovir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17216838
    [No Abstract]   [Full Text] [Related]  

  • 46. Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.
    AIDS Patient Care STDS; 2010 Jun; 24(6):395-6. PubMed ID: 20575158
    [No Abstract]   [Full Text] [Related]  

  • 47. Ethical challenges of preexposure prophylaxis for HIV.
    Jay JS; Gostin LO
    JAMA; 2012 Sep; 308(9):867-8. PubMed ID: 22847147
    [No Abstract]   [Full Text] [Related]  

  • 48. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Collaboration begins on combined drug.
    AIDS Patient Care STDS; 2005 Feb; 19(2):129. PubMed ID: 15747431
    [No Abstract]   [Full Text] [Related]  

  • 50. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
    Landman GW; Soonawala D
    Clin Infect Dis; 2010 Apr; 50(8):1200; author reply 1200. PubMed ID: 20233045
    [No Abstract]   [Full Text] [Related]  

  • 52. [Tenofovir--a new option for combination therapy].
    Polk B
    Med Monatsschr Pharm; 2002 Apr; 25(4):140-1. PubMed ID: 12017127
    [No Abstract]   [Full Text] [Related]  

  • 53. AIDS research. Complexity surrounds HIV prevention advances.
    Cohen J
    Science; 2011 Jul; 333(6041):393. PubMed ID: 21778370
    [No Abstract]   [Full Text] [Related]  

  • 54. New once-a-day drugs: Truvada and Epzicom.
    Berger DS
    Posit Aware; 2004; 15(6):38-9. PubMed ID: 15619773
    [No Abstract]   [Full Text] [Related]  

  • 55. Second complete once-daily single tablet therapy in development.
    AIDS Patient Care STDS; 2009 Aug; 23(8):680. PubMed ID: 19694037
    [No Abstract]   [Full Text] [Related]  

  • 56. In brief: Truvada for HIV prevention.
    Med Lett Drugs Ther; 2012 Aug; 54(1396):63-4. PubMed ID: 22869292
    [No Abstract]   [Full Text] [Related]  

  • 57. PrEP trial in women halted due to doubts that it could show efficacy.
    McEnery R
    IAVI Rep; 2011; 15(2):21. PubMed ID: 21608329
    [No Abstract]   [Full Text] [Related]  

  • 58. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
    Cohen J
    Science; 2010 Dec; 330(6009):1298-9. PubMed ID: 21127220
    [No Abstract]   [Full Text] [Related]  

  • 59. Medicines Control Council and registration backlog of antiretrovirals.
    Gosling J
    S Afr Med J; 2007 Apr; 97(4):232. PubMed ID: 17446940
    [No Abstract]   [Full Text] [Related]  

  • 60. Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges?
    Curran JW; Crosby RA
    Am J Prev Med; 2013 Jan; 44(1 Suppl 2):S163-6. PubMed ID: 23253761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.